NTRA News and Press, Natera Inc. From 09/07/21

Natera's Signatera® Test Selected for NRG Oncology's Landmark CIRCULATE-US Study of MRD-Guided Treatment in Stage II-III Colon Cancer Pivotal clinical trial aims to establish a new standard of care for stage II and III colon cancer patients PR Newswire AUSTIN,...

The precipitous cost decline of next-generation DNA sequencing has supercharged our understanding of tumor biology. The strange biology that makes it dangerous also gives scientists the opportunity to detect cancer earlier. The exponential cost declines associated with NGS, AI, an...

Natera Announces the Validation and Launch of the Prospera™ Heart Transplant Assessment Test Prospera Heart identifies rejection with exceptional performance from a single test, eliminating the need to combine two tests for each patient PR Newswire AUSTIN, T...

The following slide deck was published by Natera, Inc. in conjunction with their 2021 Q2 earnings call. For further details see: Natera, Inc. 2021 Q2 - Results - Earnings Call Presentation

Natera, Inc. (NTRA) Q2 2021 Earnings Conference Call August 5, 2021 04:30 PM ET Company Participants Michael Brophy - Chief Financial Officer Steve Chapman - Chief Executive Officer Conference Call Participants Tejas Savant - Morgan Stanley Tycho Peterson - JPMorgan Catherine Schulte - Baird ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Illumina’s (NASDAQ: ILMN ) strong growth and tremendous potential make ILMN stock worth buying. Source: Shutterstock It’s true that the company’s shares are not at all cheap. Still, the dema...

Natera (NASDAQ:NTRA): Q2 GAAP EPS of -$1.32 misses by $0.20. Revenue of $142.03M (+64.3% Y/Y) beats by $11.16M. Press Release For further details see: Natera EPS misses by $0.20, beats on revenue

Natera Reports Second Quarter 2021 Financial Results PR Newswire AUSTIN, Texas , Aug. 5, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ:  NTRA), a pioneer and global leader in cell-free DNA testing, today reported financial results for the second quarter ended ...

Natera Announces Use of Signatera® as a Companion Diagnostic in GSK's Phase III ZEST Trial for Niraparib in Early-Stage Breast Cancer PR Newswire AUSTIN, Texas , Aug. 4, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cel...

Natera Announces Second Quarter 2021 Earnings Conference Call PR Newswire AUSTIN, Texas , July 29, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will release results for its sec...